CeriBell, Inc. (NASDAQ:CBLL) Receives $24.67 Average Price Target from Analysts

CeriBell, Inc. (NASDAQ:CBLL) has received a consensus rating of “Moderate Buy” from the seven brokerages that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, five have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $24.6667.

CBLL has been the topic of several recent analyst reports. JPMorgan Chase & Co. dropped their target price on CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. BTIG Research reiterated a “buy” rating and issued a $30.00 price objective on shares of CeriBell in a research report on Wednesday, January 28th. Raymond James Financial assumed coverage on CeriBell in a report on Tuesday, October 21st. They issued a “strong-buy” rating and a $19.00 target price for the company. TD Cowen reaffirmed a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. Finally, Canaccord Genuity Group raised their price objective on shares of CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th.

Insider Buying and Selling at CeriBell

In other CeriBell news, Director Josef Parvizi sold 25,000 shares of the business’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $22.94, for a total transaction of $573,500.00. Following the sale, the director directly owned 747,652 shares in the company, valued at approximately $17,151,136.88. The trade was a 3.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Xingjuan Chao sold 79,000 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $21.27, for a total value of $1,680,330.00. Following the completion of the transaction, the chief executive officer owned 741,248 shares of the company’s stock, valued at approximately $15,766,344.96. This represents a 9.63% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 380,768 shares of company stock worth $7,418,070. Corporate insiders own 20.10% of the company’s stock.

Institutional Investors Weigh In On CeriBell

Large investors have recently added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in CeriBell during the third quarter worth about $33,000. CWM LLC increased its stake in shares of CeriBell by 1,178.5% during the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock worth $40,000 after purchasing an additional 1,697 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after purchasing an additional 1,801 shares during the last quarter. Ameritas Investment Partners Inc. lifted its stake in CeriBell by 97.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock valued at $48,000 after buying an additional 1,256 shares in the last quarter. Finally, Larson Financial Group LLC grew its holdings in CeriBell by 1,403.1% during the 4th quarter. Larson Financial Group LLC now owns 2,871 shares of the company’s stock valued at $63,000 after buying an additional 2,680 shares during the last quarter.

CeriBell Trading Up 4.2%

Shares of CeriBell stock opened at $20.15 on Thursday. The firm has a market cap of $747.57 million, a price-to-earnings ratio of -13.34 and a beta of 1.03. CeriBell has a 52-week low of $10.01 and a 52-week high of $26.04. The company’s 50-day simple moving average is $21.17 and its 200-day simple moving average is $15.68. The company has a quick ratio of 12.25, a current ratio of 12.65 and a debt-to-equity ratio of 0.12.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.